IGM Biosciences to Present at the Jefferies Healthcare Conference

MOUNTAIN VIEW, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that Fred

GlobeNewswireMay 29 07:00 ET

In-Depth Examination Of 6 Analyst Recommendations For IGM Biosciences

IGM Biosciences (NASDAQ:IGMS) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.The table below offers a condensed view of the

BenzingaMay 24 10:00 ET

H.C. Wainwright Maintains IGM Biosciences(IGMS.US) With Hold Rating, Maintains Target Price $12

H.C. Wainwright analyst Robert Burns maintains $IGM Biosciences(IGMS.US)$ with a hold rating, and maintains the target price at $12.According to TipRanks data, the analyst has a success rate of 23.4%

moomoo NewsMay 24 06:32 ET

IGM Biosciences Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

IGM Biosciences Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

Dow JonesMay 24 06:31 ET

Maintaining Hold on IGM Biosciences: Assessing Acquisition Impact and Awaiting Clinical Data

TipRanksMay 24 06:26 ET

Express News | HC Wainwright & Co. Reiterates Neutral on IGM Biosciences, Maintains $12 Price Target

BenzingaMay 24 06:22 ET